Lumos Pharma, Inc. (NASDAQ:LUMO – Get Rating) – Cantor Fitzgerald issued their FY2023 EPS estimates for shares of Lumos Pharma in a report issued on Monday, June 6th. Cantor Fitzgerald analyst C. Duncan anticipates that the company will post earnings per share of ($4.25) for the year.
NASDAQ LUMO opened at $7.94 on Wednesday. The stock has a 50-day moving average of $8.32 and a two-hundred day moving average of $8.38. Lumos Pharma has a 1-year low of $6.15 and a 1-year high of $12.05.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC boosted its stake in shares of Lumos Pharma by 22.3% in the 3rd quarter. Geode Capital Management LLC now owns 28,356 shares of the company’s stock valued at $269,000 after buying an additional 5,164 shares during the period. PVG Asset Management Corp purchased a new stake in Lumos Pharma in the fourth quarter valued at approximately $71,000. Envestnet Asset Management Inc. purchased a new stake in Lumos Pharma in the fourth quarter valued at approximately $72,000. Citadel Advisors LLC purchased a new stake in Lumos Pharma in the third quarter valued at approximately $113,000. Finally, Millennium Management LLC purchased a new stake in Lumos Pharma in the third quarter valued at approximately $146,000. Institutional investors and hedge funds own 38.35% of the company’s stock.
About Lumos Pharma (Get Rating)
Lumos Pharma, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders.
- Get a free copy of the StockNews.com research report on Lumos Pharma (LUMO)
- Heavy Buying Points to Upside for These 3 Stocks
- 3 Intriguing Stocks With Sub-10 P/E Ratios
- Snap Inc: Revised Guidance & Steeping Losses
- Time to Buy Take-Two Interactive Stock
- 3 Software Plays Showing Signs of Recovery
Receive News & Ratings for Lumos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lumos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.